Should pharma pay the NIH royalties?

Looking past 2010, when more than $10 billion in fresh federal research funds runs out, the new head of the NIH is hatching a plan to gain a predictable flow of money to back an enlarged commitment to the country's researchers. And one way that the NIH could gain extra financial support, Dr. Francis Collins suggests, is by claiming a royalty from drugs that are developed following federally-supported research efforts. Report